Abstract
As new antidiabetic drugs,glucagon-like peptide-1 (GLP-1) receptor agonists have been widely used.Recent studies suggest that these drugs can reduce transaminase level to improve nonalcoholic fatty liver disease by improving blood lipid levels,decreasing the content of fat,reducing fatty degeneration of the liver,the degree of liver fibrosis and cell death. Key words: GLP-1 receptor agonist; Liver function; Fat content; Nonalcoholic fatty Liver disease
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
